U-63557A
| 中文名称 | U-63557A |
|---|---|
| 中文同义词 | 化合物 T11339;化合物FUREGRELATE SODIUM |
| 英文名称 | U-63557A |
| 英文同义词 | SODIUM FUREGRELATE;U-63557A;FUREGRELATE SODIUM;FUREGRELATE SODIUM SALT;5-(3-PYRIDINYLMETHYL)-2-BENZOFURANCARBOXYLIC ACID, SODIUM SALT;5-[3,PYRIDINYLMETHYL]BENZO-FURAN-CARBOXYLIC ACID SODIUM SALT;furegralate sodium;5-(3-Pyridinylmethyl)benzofurancarboxylic acid sodium-potassium salt |
| CAS号 | 85666-17-7 |
| 分子式 | C15H12NNaO3 |
| 分子量 | 277.25 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 85666-17-7.mol |
| 结构式 |  |
U-63557A 性质
| 储存条件 | −20°C |
|---|---|
| 溶解度 | DMF：>25mg/mL； DMSO：>21mg/mL；乙醇：>14.5mg/mL； PBS pH 7.2：>16.5 mg/mL |
| 形态 | 白色至类白色结晶固体。 |
| 水溶解性 | Soluble in water at approximately 15mg/ml |
Furegrelate Sodium (U-63557A) 是一种有效的、口服的、选择性的血栓素合酶 (thromboxane synthase) 抑制剂。Furegrelate Sodium 抑制人血小板微粒体血栓素 A2 (TxA2) 合酶，其 IC50 为 15 nM。Furegrelate Sodium 正在开发作为抗血小板药物。
Furegrelate Sodium (U-63557A) (1-5 mg/kg; Oral) prevents blockage of the coronary artery.
Furegrelate Sodium (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused platelet aggregation.
Furegrelate Sodium blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature.
Furegrelate also is orally available, has a long half-life of 4.2–5.8 hours in adult humans (compared to several other therapies for PAH including nitric oxide and prostacyclin analogs), and reportedly is highly specific for its target enzyme.
| Animal Model: | Mongrel dogs (19-30 kg) |
| Dosage: | 1-5 mg/kg |
| Administration: | Oral (via a gastric tube) |
| Result: | Prevented blockage of the coronary artery. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-106080A | U-63557A Furegrelate sodium | 85666-17-7 | 5mg | 600元 |
| 2024/04/30 | HY-106080A | U-63557A Furegrelate sodium | 85666-17-7 | 10 mM * 1 mLin DMSO | 660元 |